Africa Digital Media Awards

Global site navigation

Local editions

Trump drug price plan could nix investment, warns Roche
Economy

Trump drug price plan could nix investment, warns Roche

by  AFP
2 min read
Roche says President Donald Trump's new prescription drugs policy could hit its investment plans
Roche says President Donald Trump's new prescription drugs policy could hit its investment plans. Photo: SEBASTIEN BOZON / AFP
Source: AFP

CHECK OUT: Understand How to Create a Steady Income with Subscriptions and Exclusive Content — So You’re Not Just Hoping for the Next Payout, You Know It’s Coming

President Donald Trump's plans to dramatically slash drug prices for Americans could make Swiss pharmaceutical giant Roche cancel major investments in the United States, it said Wednesday.

Trump signed an executive order Monday aimed at bringing down the notoriously high prescription drug prices paid by US consumers, news that rattled pharmaceutical companies.

Swiss newspaper NZZ reported Trump's move could lead Roche to reassess plans it announced just last month to invest $50 billion in the United States over five years.

Roche, the world leader in cancer treatments, said in a statement it did not expect Trump's new drugs policy to hurt its business in 2025.

"However, should the proposed EO (executive order) go into effect, Roche's ability to fund the significant investments previously announced in the US will be in question," it said.

Trump has been pushing foreign firms to invest more in the United States, saying the way to avoid his tariff assault on foreign-made goods is to produce them on US soil instead.

PAY ATTENTION: Follow us on Instagram - get the most important news directly in your favourite app!

Prescription drugs were not targeted in Trump's "Liberation Day" tariff announcements.

Still, Roche appeared to take heed with its April investment announcement, which came just after fellow Swiss rival Novartis said it would increase investment in the United States by $23 billion over five years.

The United States is a key market for Roche, accounting for more than half its pharmaceutical division's revenues.

Roche's US subsidiary Genentech announced a $700-million project Monday to build a new plant in North Carolina, which it says would employ 400 people.

Source: AFP

Authors:
AFP avatar

AFP AFP text, photo, graphic, audio or video material shall not be published, broadcast, rewritten for broadcast or publication or redistributed directly or indirectly in any medium. AFP news material may not be stored in whole or in part in a computer or otherwise except for personal and non-commercial use. AFP will not be held liable for any delays, inaccuracies, errors or omissions in any AFP news material or in transmission or delivery of all or any part thereof or for any damages whatsoever. As a newswire service, AFP does not obtain releases from subjects, individuals, groups or entities contained in its photographs, videos, graphics or quoted in its texts. Further, no clearance is obtained from the owners of any trademarks or copyrighted materials whose marks and materials are included in AFP material. Therefore you will be solely responsible for obtaining any and all necessary releases from whatever individuals and/or entities necessary for any uses of AFP material.

Hot: